Healthcare
Nippon Shinyaku Co., Ltd.(NPPNY)
Live Price
Offline$6.16
+0.00% today
1Y Change
+15.25%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $322.18B
- Revenue Growth
- +8.1%
- EPS Growth
- +25.9%
- Dividend Yield
- 2.6%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nippon Shinyaku Co., Ltd. (NPPNY) is a Healthcare stock with a market cap of $322.18B and listed on OTC. The stock last traded around $6.16 and up 15.3% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +8.1%, EPS growth of +25.9%, a dividend yield of 2.6%. What stands out right now is revenue +8.1%, EPS +25.9%, free cash flow +393.6% with operating margin 21.5% and ROIC 9.9%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 10.8 and price/sales 1.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines NPPNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.1% vs +7.6% peer median
Operating Margin
Above sector median
+21.5% vs +19.4% peer median
P/E
Below sector median
10.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +8.1% and EPS at +25.9%, with operating margin around 21.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +0.0% | +0.0% | -25.2% |
2026 Feb 5, 2026 | โ | +0.0% | -7.1% | -15.2% |
2025 Nov 11, 2025 | โ | +0.0% | +13.5% | +84.3% |
Benchmark Edge
NPPNY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NPPNY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NPPNY Max Drawdown
-59.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NPPNY and SPY.
Company Overview
Nippon Shinyaku Co., Ltd.
Other OTC
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
- Leadership
- Toru Nakai
- IPO Date
- Nov 16, 2016
- Employees
- 2.2k
- Street Address
- 14, Nishinosho-Monguchi-cho
- Mailing
- Kyoto, 601-8550
- Region
- Kyoto, JP
- Reporting Currency
- USD
- Investor Line
- 81 7 5321 1111
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 10.8
- EV/EBITDA
- 6.3
- Price/Sales
- 1.9
- Price/Book
- 1.1
Growth
- Revenue
- +8.1%
- EPS
- +25.9%
- Free Cash Flow
- +393.6%
Profitability
- Gross Margin
- 67.3%
- Operating Margin
- 21.5%
- Net Margin
- 18.0%
- ROE
- 11.5%
- ROIC
- 9.9%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 5.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.